IP Library Granted Patent US 10,197,583
Granted Patent B2
US 10,197,583 · App. 15/484,754 · Granted Feb 5, 2019

Hydroxycholesterol immunoassay

Inventors: Michael C. Mullenix (Saline, MI); Robert Elliot Zipkin (Wynnewood, PA); Jeffrey Kroll Adams (Fort Washington, PA); Wayne Forrest Patton (Dix Hills, NY); James J. Donegan (Long Beach, NY)
Assignee: Enzo Life Sciences, Inc.
G01N33/92C07J9/00C07J43/003C07K16/18C07K16/44G01N33/5308G01N33/56966C07K2317/21G01N2800/285G01N2800/2835G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,197,583
App. No.
15/484,754
Granted
Feb 5, 2019
Kind
B2
Abstract

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

Claims (2)

1. A compound having the structure

2. A compound having the structure

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2017
From: MULLENIX, MICHAEL C.; ZIPKIN, ROBERT ELLIOT; ADAMS, JEFFREY KROLL; PATTON, WAYNE FORREST; DONEGAN, JAMES J.
To: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM
Reel/Frame 042320/0562 →
Continuity (3)
Continuation 14572061 · Dec 16, 2014
Division 12927206 · Nov 9, 2010
Related Publication 20170219612A1 · Aug 3, 2017